Page last updated: 2024-09-04

nk 611 and podophyllotoxin

nk 611 has been researched along with podophyllotoxin in 10 studies

Compound Research Comparison

Studies
(nk 611)
Trials
(nk 611)
Recent Studies (post-2010)
(nk 611)
Studies
(podophyllotoxin)
Trials
(podophyllotoxin)
Recent Studies (post-2010) (podophyllotoxin)
12503,119226782

Protein Interaction Comparison

ProteinTaxonomynk 611 (IC50)podophyllotoxin (IC50)
nuclear receptor subfamily 0 group B member 1Homo sapiens (human)2.145
Tubulin alpha-1A chainSus scrofa (pig)0.6733
Tubulin beta chainSus scrofa (pig)0.622
Glucocorticoid receptorHomo sapiens (human)0.014
Tubulin beta-4A chainHomo sapiens (human)1.7233
Tubulin beta chainHomo sapiens (human)1.7233
Cytochrome P450 3A4Homo sapiens (human)0.6
Tubulin alpha-3C chainHomo sapiens (human)1.7233
Cytochrome P450 2C9 Homo sapiens (human)4
Cytochrome P450 2C19Homo sapiens (human)5
Tubulin alpha-1B chainHomo sapiens (human)1.7233
Tubulin alpha-4A chainHomo sapiens (human)1.7233
Tubulin beta-4B chainHomo sapiens (human)1.7233
Tubulin beta-3 chainHomo sapiens (human)1.7233
Tubulin beta-2A chainHomo sapiens (human)1.7233
Tubulin beta-8 chainHomo sapiens (human)1.7233
Calcium-activated potassium channel subunit alpha-1Rattus norvegicus (Norway rat)0.56
Tubulin beta-2B chainBos taurus (cattle)0.8685
Tubulin alpha-3E chainHomo sapiens (human)1.7233
Tubulin alpha-1A chainHomo sapiens (human)1.7233
Similar to alpha-tubulin isoform 1 Bos taurus (cattle)0.907
Similar to alpha-tubulin isoform 1 Bos taurus (cattle)0.7744
Tubulin alpha-1C chainHomo sapiens (human)1.7233
Tubulin beta-6 chainHomo sapiens (human)1.7233
Tubulin beta-2B chainHomo sapiens (human)1.7233
Tubulin beta-1 chainHomo sapiens (human)1.7233

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's10 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Depenbrock, H; Hanauske, AR; Kaeser-Fröhlich, A; Lehmer, A; Rastetter, J; Rotter, M; Schneider, P; Wüster, KC1
D'Incalci, M; De Fusco, M; Gentili, D; Reichert, S; Zucchetti, M1
D'Incalci, M; De Fusco, M; Fröhlich, A; Reichert, S; Sessa, C; Zucchetti, M1
Hossfeld, DK; Hüttmann, A; Mross, K1
Gemba, K; Kiura, K; Matsumura, T; Moritaka, T; Ohnoshi, T; Segawa, Y; Shibayama, T; Tabata, M; Takigawa, N; Ueoka, H1
Burk, K; Hanauske, AR; Herbst, K; Hossfeld, DK; Hüttmann, A; Manegold, C; Mross, K; Schilling, T1
Cavalli, F; D'Incalci, M; De Fusco, M; de Jong, J; Hanauske, A; Kaeser-Fröhlich, A; Pagani, O; Sessa, C; Zucchetti, M1
Hanauske, AR; Kaeser-Fröhlich, A; Rassmann, I; Rastetter, J; Schilling, T; Schrödel, H; Zucchetti, M1
Capranico, G; D'Incalci, M; Garattini, S; Giaccone, G; Zunino, F1
Daley, L; Demerseman, P; Etiévant, C; Guminski, Y; Hill, BT; Imbert, T; Kruczynski, A; Monneret, C1

Reviews

1 review(s) available for nk 611 and podophyllotoxin

ArticleYear
DNA topoisomerase II poisons and inhibitors.
    Cancer chemotherapy and biological response modifiers, 1997, Volume: 17

    Topics: Animals; Antineoplastic Agents; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Podophyllotoxin; Topoisomerase II Inhibitors

1997

Trials

4 trial(s) available for nk 611 and podophyllotoxin

ArticleYear
High-performance liquid chromatographic assay for the determination of the novel etoposide derivative dimethylaminoetoposide (NK611) and its metabolites in urine of cancer patients.
    Journal of chromatography. B, Biomedical applications, 1995, Feb-17, Volume: 664, Issue:2

    Topics: Administration, Oral; Antineoplastic Agents; Chromatography, High Pressure Liquid; Humans; Injections, Intravenous; Neoplasms; Podophyllotoxin; Quality Control; Spectrophotometry, Ultraviolet

1995
Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH.
    Cancer chemotherapy and pharmacology, 1996, Volume: 38, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Cell Count; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Germany; Half-Life; Humans; Infusion Pumps; Infusions, Intravenous; Leukocytes; Male; Middle Aged; Molecular Weight; Neutrophils; Podophyllotoxin; Protein Binding; Structure-Activity Relationship

1996
Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative.
    Cancer chemotherapy and pharmacology, 1996, Volume: 38, Issue:6

    Topics: Administration, Oral; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Podophyllotoxin; Thrombocytopenia

1996
Clinical and pharmacokinetic phase I trial of oral dimethylaminoetoposide (NK611) administered for 21 days every 35 days.
    Investigational new drugs, 1996, Volume: 14, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Cell Count; Drug Administration Schedule; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Podophyllotoxin

1996

Other Studies

5 other study(ies) available for nk 611 and podophyllotoxin

ArticleYear
Activity of NK 611, a new epipodophyllotoxin derivative, against colony forming units from freshly explanted human tumours in vitro.
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:10

    Topics: Antineoplastic Agents; Cell Survival; Dose-Response Relationship, Drug; Etoposide; Humans; Neoplastic Stem Cells; Podophyllotoxin; Tumor Stem Cell Assay

1995
High-performance liquid chromatographic assay for the determination of the novel podophyllotoxin derivative dimethylaminoetoposide (NK611) in human plasma.
    Journal of chromatography. B, Biomedical applications, 1994, Mar-18, Volume: 654, Issue:1

    Topics: Antineoplastic Agents; Biological Availability; Chromatography, High Pressure Liquid; Humans; Metabolic Clearance Rate; Neoplasms; Podophyllotoxin; Quality Control; Sensitivity and Specificity

1994
Determination of the new podophyllotoxin derivative NK 611 in plasma by high-performance liquid chromatography with ultraviolet detection.
    Journal of chromatography, 1993, Oct-29, Volume: 620, Issue:2

    Topics: Antineoplastic Agents; Artifacts; Chromatography, High Pressure Liquid; Humans; Molecular Structure; Podophyllotoxin; Reproducibility of Results; Spectrophotometry, Ultraviolet

1993
[In vitro comparison of podophyllotoxin analogues; etoposide, teniposide and NK 611 using human lung cancer cell lines].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cell Division; Drug Resistance; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Podophyllotoxin; Teniposide; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured

1993
Synthesis and antitumor activity of new glycosides of epipodophyllotoxin, analogues of etoposide, and NK 611.
    Journal of medicinal chemistry, 1998, Nov-05, Volume: 41, Issue:23

    Topics: Animals; Antineoplastic Agents; Biopolymers; Drug Screening Assays, Antitumor; Female; Glycosides; Glycosylation; Humans; Inhibitory Concentration 50; Leukemia L1210; Leukemia P388; Mice; Mice, Inbred DBA; Podophyllotoxin; Stereoisomerism; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Transplantation, Heterologous; Tubulin; Tumor Cells, Cultured

1998